Fungal infection drug for lung transplant recipients may increase cancer, death risk
the ONA take:
A prescription drug that is commonly used to treat fungal infections in lung transplant recipients may significantly increase the risk for skin cancer and even death, according to a recent study published in the American Journal of Transplantation.
Researchers led by Sarah Arron, MD, PhD, of the UCSF High Risk Skin Cancer Clinic looked at 455 single-, double- or heart-lung transplant recipients who received their transplant between October 1991 to December 2012.
Patients were analyzed for voriconazole exposure and its impact on cutaneous squamous cell carcinoma and mortality compared to the general population.
They found that exposure to the drug resulted in a 73% greater risk for SCC, with each additional 30-day exposure increasing the risk by 3%.
While the drug significantly reduced risk of Aspergillus colonization, especially within the first year of transplantation along with a reduced all-cause mortality in these patients, it did not reduce risk of aspergillosis.
“It is important for physicians to be aware of the impact of voriconzaole on these outcomes,” said Dr. Arron. “We recommend that all providers counsel lung transplant recipients on skin cancer risk and photoprotection in addition to scheduling routine skin cancer screening with a trained dermatologist after transplantation.”
Prescription drug that is commonly used to treat fungal infections in lung transplant recipients may significantly increase the risk for skin cancer.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|